News | August 09, 2022
Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Revolutionary ovarian cancer rapid test available Q4 2022
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
The plant is expected to start commercial operations from Q4FY24
Subscribe To Our Newsletter & Stay Updated
